Open letters
Open letters
Open letters
Joint response from European Medicines Regulatory Network to letter from Health Action International and other health groups on missing clinical trial results in CTIS
Human medicines European public assessment report (EPAR): Libmyris, adalimumab, Date of authorisation: 12/11/2021, Revision: 10, Status: Authorised
PSUSA/00002298/202512
PSUSA/00001720/202511
PSUSA/00000409/202512
Human medicines European public assessment report (EPAR): Idacio, adalimumab, Date of authorisation: 02/04/2019, Revision: 15, Status: Authorised
PSUSA/00003102/202511
EMEA-003356-PIP01-22
Human medicines European public assessment report (EPAR): Kostaive, zapomeran, Date of authorisation: 12/02/2025, Revision: 5, Status: Authorised